ChartRow logo
DMRA
$21.96+3.29%
as of close, Oct 27, 2026
☾ AH $21.96 +3.29%
PeersMRNALLYMDTUNHJNJTMO
Share this page

Damora Therapeutics Inc. trailing returns

How Damora Therapeutics Inc. (DMRA) has performed over the last day, week, month and year, over 5 years, and since inception, through October 27, 2026 — price return and dividends side by side, with the worst drop inside each window.

Trailing returns by period#

To 2026-10-27. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.

PeriodPriceDivsTotalWorst drop
1 day+3.3%+0.0%+3.3%—
5 days+6.2%+0.0%+6.2%-2.9%Oct 23
1 month+6.3%+0.0%+6.3%-13.4%Oct 14
YTD-4.6%+0.0%-4.6%-44.1%Oct 14
1 year+199.0%+0.0%+199.0%-46.9%Mar 2026
5 years-23.3%+0.0%-23.3%-73.5%-97.5%Apr 2025
Since inception (2020)-37.7%+0.0%-37.7%-94.1%-99.5%Apr 2025

Growth of DMRA#

Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.

  • 5 years-23.3%/year · -73.5%

Methodology#

Trailing returns measure from the closest close about N years before the latest close (2026-10-27). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in DMRA's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.

FAQ#

What is Damora Therapeutics Inc.'s return since inception?
Since 2020, Damora Therapeutics Inc. (DMRA) has compounded at about -37.7% a year — -94.1% in total.

More on Damora Therapeutics Inc.